Loading clinical trials...
Loading clinical trials...
An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Cahaba Dermatology & Skin Health Center, LLC
Birmingham, Alabama, United States
California Allergy and Asthma Medical Group
Los Angeles, California, United States
Integrative Skin Science and Research
Sacramento, California, United States
West Dermatology Research Center
San Diego, California, United States
Advanced Clinical Research Institute
Tampa, Florida, United States
Aeroallergy Research Laboratories of Savannah, Inc.
Savannah, Georgia, United States
Treasure Valley Medical Research
Boise, Idaho, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
Southern Indiana Clinical Trials
New Albany, Indiana, United States
Indiana Clinical Trials Center, P.C.
Plainfield, Indiana, United States
Start Date
August 14, 2024
Primary Completion Date
May 8, 2025
Completion Date
May 8, 2025
Last Updated
June 18, 2025
30
ACTUAL participants
Oral EVO756
DRUG
Lead Sponsor
Evommune, Inc.
NCT07266402
NCT06931405
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions